This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
JANX011 is administered subcutaneously, one time.
CMAX
Adelaide, South Australia, Australia
RECRUITINGIncidence, severity, and relatedness of TEAEs, treatment-emergent SAEs, and treatment-emergent AESIs.
Time frame: Up to 85 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.